NYR Insider Trading (Nyrada)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00
Nyrada Share Price & Price History
Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET
Trading Isn’t Getting Easier–But Options Just Did!
From Tradewins | Ad
Options trading expert and trading champion Chuck Hughes has done it again with his guide, “Options Trading Made Easy”!
Made for new traders, this guide explains options–plus the consistent profits you could make–in easy to understand terms.
Don’t keep waiting for it to get easier–get the e-book here!
>>>
Nyrada Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/29/2021 | Ruediger Weseloh | Insider | Issued | 100,000 | A$0.26 | A$26,000.00 | | |
| 2/23/2021 | Marcus Frampton | Insider | Buy | 25,000 | A$0.36 | A$8,925.00 | | |
| 9/10/2020 | John Moore | Insider | Buy | 32,500 | A$0.21 | A$6,825.00 | | |
| 4/23/2020 | John Moore | Insider | Buy | 35,000 | A$0.17 | A$5,880.00 | | |
Trading Isn’t Getting Easier–But Options Just Did!
From Tradewins | Ad
Options trading expert and trading champion Chuck Hughes has done it again with his guide, “Options Trading Made Easy”!
Made for new traders, this guide explains options–plus the consistent profits you could make–in easy to understand terms.
Don’t keep waiting for it to get easier–get the e-book here!
>>>
SEC Filings (Institutional Ownership Changes) for Nyrada (ASX:NYR)
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in the drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; NYR-BI01, a neuroprotectant drug, to reduce the disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company has collaboration with Walter Reed Army Institute of Research and University of New South Wales, Sydney for advancement of preclinical neuroprotection compound for traumatic brain injury. Nyrada Inc. was incorporated in 2017 and is based in Gordon, Australia.
Read More on Nyrada
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
65,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Nyrada?
